Multiparametric MRI, sodium MRI, and PSMA PET of prostate cancer with histological validation of Gleason grade
Josephine Tan1, Alireza Akbari1, Matthew Fox2, Mena Gaed3, Madeleine Moussa4, Jose A Gomez4, Zahra Kassam5, William Pavlosky5, Joseph L Chin6, Stephen Pautler6, Nicholas Power6, Aaron D Ward1,2, Glenn S Bauman1,2, Jonathan D Thiessen1,2,5, and Timothy J Scholl1,3,7
1Medical Biophysics, University of Western Ontario, London, ON, Canada, 2Lawson Health Research Institute, London, ON, Canada, 3Robarts Research Institute, University of Western Ontario, London, ON, Canada, 4Pathology and Laboratory Medicine, University of Western Ontario, London, ON, Canada, 5Medical Imaging, University of Western Ontario, London, ON, Canada, 6Surgery, Division of Urology, University of Western Ontario, London, ON, Canada, 7Ontario Institute for Cancer Research, Toronto, ON, Canada
This abstract focuses on the development of an imaging assay based on multiparametric MRI and sodium (23Na) MRI to discriminate between low- and high-grade prostate cancer (PCa) lesions, using Gleason grade defined by whole-mount histopathology as the gold standard and PET targeting the prostate-specific membrane antigen (PSMA) as a validation. Data from the first patient (Gleason score 7) demonstrates that PSMA-PET may be superior in detecting PCa lesions in the transition zone and distant metastases while the sensitivity of the current 23Na radiofrequency system in this study is limited to lesions in the peripheral zone of the prostate.
This abstract and the presentation materials are available to members only;
a login is required.